TACR1 and hepatoblastoma: In the context of cancer treatment, the antitumor influence of AP, as an oral NK1R antagonist, opens up a new avenue to cancer treatment, including melanoma, hepatoblastoma, pancreas, lung, and breast malignancy [21, 28, 43–46].